University of Giessen

A Phase II study by Hamlet BioPharma shows similar outcomes between immunotherapy and antibiotic treatment for recurrent acute cystitis, potentially reducing antibiotic use. The study, in collaboration with the University of Giessen, highlights the benefits of immunotherapy in treating this common infection, which affects many women, and could mitigate antibiotic resistance.

34% of 103 MS patients on ofatumumab experienced end-of-dose phenomena, linked to higher disability, longer disease duration, and older age. Ofatumumab showed lower odds of wearing-off effect vs. ocrelizumab and higher persistence rates compared to other DMTs.